
Opinion|Videos|June 5, 2024
Evolving Commercialization and Distribution Models for PDTs
The panel discusses the challenges of delivering prescription digital therapeutics (PDTs) to patients, challenges caused by PDTs being considered behavioral health benefits, pharmacy benefits, medical benefits, and durable medical equipment benefits.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
2
Patients Face New Care Complexities as DTC Options Expand
3
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
4
Louisiana Delivers Innovative Cancer Treatments, but Ensuring Access Is a Work in Progress
5














































